Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9. ARIC PCSK9 Loss-of-Function Mutations, LDL-C, and CHD Risk. PCSK9-Directed Therapies in Development. Effects of Evolocumab (AMG-145) on LDL-C Levels Phase 1b Study Design. - PowerPoint PPT Presentation
Citation preview
Dallas Heart StudyLipid Characteristics of Blacks With Nonsense
Mutations in PCSK9
ARICPCSK9 Loss-of-Function Mutations, LDL-C, and
CHD Risk
PCSK9-Directed Therapies in Development
Effects of Evolocumab (AMG-145) on LDL-C Levels
Phase 1b Study Design
Evolocumab -- Phase 1bChange in LDL-C at 2- and 4-Week Dosing
Intervals on Statin Therapy
PCSK9 InhibitorsPhase 2
MENDELEvolocumab Phase 2 Monotherapy in Patients
With Hypercholesterolemia
MENDELStudy Design
MENDELEvolocumab Monotherapy for Hypercholesterolemia
PCSK9 InhibitorsPhase 2
Alirocumab (SAR236553) Add-on to Atorvastatin
AlirocumabChange in LDL-C at 2- and 4-Week Dosing Intervals on
Atorvastatin
Alirocumab on Top of Atorvastatin in Primary Hypercholesterolemia
LAPLACE-TIMI 57Evolocumab in Combination With Statin in
Patients With Hypercholesterolemia
LAPLACE-TIMI 57 Study Design
LAPLACE-TIMI 57 Effect of Evolocumab on Percentage Change in
LDL-C From Baseline
Intravenous RN316 in Hypercholesterolemic Patients on High or Maximum-Dose Statin
Therapy Phase 2 Studies
Intravenous RN316 in Hypercholesterolemic Patients on High- or Maximum-Dose Statin Therapy
Doses Studied
Intravenous RN316 in Hypercholesterolemic Patients on
High or Maximum-Dose Statin Therapy
Pooled Results
PCSK9 InhibitorsPhase 2
GAUSSPhase 2 Evolocumab in Statin-Intolerant Patients
GAUSSEvolocumab in Statin Intolerance
PCSK9 InhibitorsPhase 2
Effect of Alirocumab on LDL-C in Heterozygous FH
RUTHERFORDPhase 2 Evolocumab in Patients With
Heterozygous FH
RUTHERFORDEffect of Evolocumab on LDL-C in Heterozygous